<DOC>
	<DOCNO>NCT02523547</DOCNO>
	<brief_summary>Open-labeled , Prospective , Randomized , Multi-center , Interventional , Phase IV study .</brief_summary>
	<brief_title>Study Evaluate Non-inferiority Cavir HBeAg ( + ) Chronic Hepatitis B Patients Treated With Baraclude</brief_title>
	<detailed_description>The purpose study evaluate non-inferiority safety term HBV DNA undetectability compare Baraclude Tab . HBeAg ( + ) chronic hepatitis B patient treat long-term Baraclude Tab .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Patients ( the19 year age ) currently take BaracludeÂ® monotherapy chronic HBV infection least 24 month &lt; HBV DNA 60 IU/mL level , HBeAg positive HBeAb negative status screen . Patients diagnose Hepatitis cancer hepatocellular carcinoma ( HCC ) Patient concomitant chronic viral infection ( HAV/Hepatitis C Virus ( HCV ) /Hepatitis D Virus ( HDV ) /HIV ) Patient document resistance mutation time screen Patient clinically confirm alcoholism , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency Wilson 's Disease . Patient receive antiviral agent include interferon Baraclude within 24 month screen study . Patient receive immunosuppressive agent within 24 week screen corticosteroid 4 week . Clinical sign indicate one following : Ccr ( CockroftGault ) &lt; 50ml/min , Total bilirubin &gt; 3.0 mg/dl , Albumin &lt; 2.7 g/dl , Prothrombin time &gt; INR 2.3 Patient pregnant breastfeed willing pregnant Patient malignancy except thyroid cancer Borderline malignancy.a history treated malignancy allowable patient 's malignancy complete remission , chemotherapy without additional surgical intervention , precede five year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>entecavir</keyword>
</DOC>